Skip to main content
. 2012 Apr;14(4):304–314. doi: 10.1111/j.1463-1326.2011.01523.x

Figure 4.

Figure 4

LEAD-5 trial: Mean change from baseline in HbA1c (%) at Week 26 by baseline body mass index category [41]. Subgroup analysis of the intent-to-treat, last observation carried forward population. LEAD, liraglutide effect and action in diabetes.